

Press Release

First ExyCell® Biopharmaceutical Facility Unveiled in Shanghai

Stuttgart, Exyte and Miltenyi Biotech recently celebrated the opening of the first ExyCell facility, the CliniMACS Cell Factory® of Miltenyi Biotec, in Shanghai, marking an important milestone. Local officials, industry leaders, and top executives from both companies attended the opening ceremony alongside some 100 guests.



Opening ceremony

Fast time to market and great flexibility are crucial in the personalized medicine market. The new facility pairs the CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell modular cleanroom to enable fast rollout of small, medium, and large-scale cell manufacturing facilities. ExyCell technology provides the underpinning for a

modular and expandable facility that readily adapts to suit biopharmaceutical manufacturers' production needs and budget without any downtime. This technology was integrated with Miltenyi Biotec's unique manufacturing platform to provide an innovative, sustainable, and effective solution for cell therapy manufacturing.

Innovations in process and facility technologies are changing the biopharmaceutical landscape in what continues to be a very dynamic market. Chris Miller, President of the Exyte Global Business Unit Biopharma and Life Sciences, said, "The new ExyCell incorporates over 50 years of Exyte experience in cleanrooms and a more recent history of successful design of traditional and modular biopharmaceuticals facilities, recognized with several ISPE Facility of the Year awards."

Exyte manufactures ExyCell modules at three locations around the world. They serve to standardize and optimize operations to use materials more efficiently and minimize waste on site for more sustainable manufacturing. Exyte's global technology team joined forces with local implementation experts in China, enabling the project team to rapidly build the ExyCell. The journey from fabrication to validation took just twelve weeks. Frank Lorenzetto, Vice President of Exyte Northeast Asia, stated, "We are excited to be involved in both the global and local biopharmaceuticals market at this amazing time in the industry, with so many new technologies and innovations becoming available."

Dr. Boris Stoffel, Member of the Management Board of Miltenyi Biotec, emphasized the importance of this facility: "As a company, it is our goal to enable our customers in their efforts to make innovative cell and gene therapies available to patients. Combining the proven CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell module will make an important contribution by helping to fast-track new therapies to the benefit of global healthcare."



About Exyte

Exyte is a global leader in the design, engineering, and delivery of facilities for high-tech industries. With a history of more than 100 years, the company has developed unique expertise in controlled and regulated environments. Exyte has a truly global footprint, serving the most technically demanding clients in markets such as semiconductors, batteries, pharmaceuticals, biotechnology, and data centers. The company offers a full range of services from consulting to managing turnkey solutions – delivered to the highest quality and safety standards. Solving the most complex challenges, Exyte forges trusted, long-lasting relationships with its clients. In 2020, Exyte generated sales of EUR 4.1 billion. The company is ideally positioned to further strengthen its market leadership with its broad industry insight and its exceptional talents. www.exyte.net

<p>Media Contact Adriana Williams Vice President Corporate Communications & Investor Relations +49 711 8804 1489 adriana.williams@exyte.net</p>	<p>Technical Queries Gordon Nicholson Director, Biopharma and Life Sciences +86 21 22201850 gordon.nicholson@exyte.net</p>
---	---

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies enable solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 3,500 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health. www.miltenyibiotec.com

<p>Media Contact Holger Bülow Corporate Communications +49 2204 8306-6680 holgerb@miltenyi.com</p>	<p>Technical Queries Jim Liu Senior Manager, MITC SH & GMP Cell Factory +86 138 1686 0461 jiml@miltenyi.com</p>
---	---